摘要
目的:了解双膦酸盐类药物在浙江省乳腺癌骨转移患者中的应用现状及趋势,为进一步促进该类药物的临床合理使用提供参考。方法:采用金额排序分析和用药频度分析方法,对抽取的浙江省11家医院2010-2015年接受双膦酸盐类药物治疗的乳腺癌骨转移患者样本处方中所使用的该类药物相关品种的使用金额、用药频度(DDDs)和日均费用(DDC)等进行统计、计算、排序及分析。结果:6年间双膦酸盐类药物的使用金额总体稳中有升(其中2011年增幅较大),2015年比2010年增加了96.26%。使用金额排前3位的品种分别是注射用唑来膦酸(进口)、注射用唑来膦酸(国产)和注射用帕米膦酸二钠,其中注射用唑来膦酸(进口)的使用金额总体基本呈上升趋势,而注射用帕米膦酸二钠的使用金额总体基本呈下降趋势。DDDs排前3位的品种分别是注射用唑来膦酸(国产)、注射用唑来膦酸(进口)和注射用帕米膦酸二钠,其中注射用唑来膦酸(国产)和注射用唑来膦酸(进口)的DDDs总体基本呈上升趋势,而注射用帕米膦酸二钠的DDDs总体基本呈下降趋势。双膦酸盐类药物各品种的B/A值介于0.33~2.00之间,其中2012-2015年注射用唑来膦酸(国产)的B/A值均为2.00,注射用唑来膦酸(进口)的B/A值均为0.50。DDC排第1、2位的品种均为注射用氯屈膦酸二钠、注射用唑来膦酸(进口)。结论:浙江省11家医院2010-2015年乳腺癌骨转移患者双膦酸盐类药物的使用金额总体稳中有升,其中疗效确切、安全性较好、价格适中的第二和第三代双膦酸盐类药物的部分品种(如注射用帕米膦酸二钠、注射用唑来膦酸等,尤其是后者)在临床使用中占优势。双膦酸盐类药物的选择与使用基本合理,但价格仍然是限制部分品种进一步广泛应用的首要因素。
OBJECTIVE:To investigate the utilization and trend of bisphosphonates drugs in patients with bone metastasis of breast cancer from Zhejiang province,so as to provide reference for the further promotion of their rational use.METHODS:The utilization of this type of drugs in 11 hospitals of Zhejiang province during 2010-2015 was analyzed statistically,counted and ranked by using the method of cost ranking analysis and DDDs analysis in the respect of amount,DDDs,DDC,etc.RESULTS:The amount of bisphosphonates drugs was increased steadily in 6 years(increasing greatly in 2011),increased by 96.26%in 2015,compared to 2010.Top 3 drugs in the list of amount were Zoledronic acid for injection(imported),Zoledronic acid for injection(domestic)and Pamidronate disodium for injection.Among them,Zoledronic acid for injection(imported)basically showed an upward trend,while Pamidronate disodium for injection showed decline trend.Top 3 drugs in the list of DDDs were Zoledronic acid for injection(domestic),Zoledronic acid for injection(imported)and Pamidronate disodium for injection;DDDs of Zoledronic acid for injection(domestic)and Zoledronic acid for injection(imported)were generally on the rise,while that of Pamidronate disodium for injection showed an overall downward trend.B/A value of bisphosphonates ranged 0.33-2.00,among which B/A value of Zoledronic acid for injection(domestic)was 2.00 and that of Zoledronic acid for injection(imported)was 0.50 during 2012-2015.The first and second drugs in the list of DDC were Clodronate disodium for injection and Zoledronic acid for injection(imported).CONCLUSIONS:The total amount of bisphosphonates drugs in patients with bone metastasis of breast cancer from 11 hospitals of Zhejiang province during 2010-2015 was increased steadily.Some varieties of second and third generation bisphosphonates with definite curative effect,good safety and reasonable price are dominant in clinical use.The selection and use of bisphosphonates is basically reasonable,but price is still the primary factor restricting the further wide application of some varieties.
作者
曹莹莹
王增
方罗
戚雅君
余佳文
骆虹
宋俞
CAO Yingying;WANG Zeng;FANG Luo;QI Yajun;YU Jiawen;LUO Hong;SONG Yu(Dept.of Pharmacy,Zhejiang Cancer Hospital,Hangzhou 310022,China)
出处
《中国药房》
CAS
北大核心
2018年第8期1061-1065,共5页
China Pharmacy
基金
国家自然科学基金资助项目(No.81773819)
浙江省中医药科技计划项目(No.浙卫发[2015]74号-2016ZA038)
